Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer

Conditions:   Ovarian Neoplasms;   Fallopian Tube Neoplasms;   Endocrine Gland Neoplasms;   Neoplasms by Site;   Neoplasms;   Genital Neoplasms, Female;   Urogenital Neoplasms;   Neoplasms, Glandular and Epithelial;   Neoplasms by Histologic Type;   Carcinoma, Ovarian Epithelial;   Ovarian Diseases;   Adnexal Diseases;   Genital Diseases, Female;   Endocrine System Diseases;   Gonadal Disorders;   Carcinoma;   Bevacizumab;   Enzyme Inhibitors;   Antineoplastic Agents;   Molecular Mechanisms of Pharmacological Action;   Angiogenesis;   BRCA1 Mutation;   BRCA2 Mutation;   Homologous Recombination Deficiency Interventions:   Drug: Niraparib;   Drug: Bevacizumab Sponsor:   Xiaoxiang Chen Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials